Development of novel cell and gene therapies

细胞工程中心(CCE)正致力于开发和改进癌症细胞疗法，包括树突状细胞(DC)疗法、嵌合抗原受体(CAR)T细胞疗法和表达肿瘤抗原特异性T细胞受体(TCR)的T细胞工程。该实验室正在努力改进用于再生医学应用的骨髓基质干细胞(BMSCs)和诱导多能干细胞(IPS)的生产方法。 树突状细胞是肿瘤疫苗的重要佐剂。CCE目前正在生产表达HER2/neu的DC，用于治疗肿瘤表达HER2/neu抗原的癌症患者。该实验室发现，一些人血浆中的因子可以抑制DC表达HER2/neu。 CCE新生产管理(NPM)实验室已经开发并正在制造几种汽车T细胞疗法。CD22-CAR T细胞和CD19/CD22双特异性T细胞正在研制中，用于治疗儿童B细胞白血病患者。CD30-CAR T细胞的制造最近已经开始。这些CAR T细胞正被用于治疗成人淋巴瘤。该实验室还开发了抗B细胞成熟抗原(BCMA)CAR T细胞和抗SLAMF7-CAR T细胞来治疗多发性骨髓瘤患者。该实验室已经开发出使用全自动仪器制造CD19/CD22-CAR T细胞的程序。 人乳头瘤病毒(HPV)感染与许多癌症有关。NPM实验室已经开发出一种方法来生产T细胞，这种T细胞表达针对HPV-16癌蛋白E7的T细胞受体(TCR)。这些细胞将用于治疗HPV相关的宫颈癌和口咽癌患者。 细胞处理实验室正在与国家眼科研究所的研究人员合作，开发从血液中分离的CD34细胞制造iPS细胞的方法，并在视网膜色素上皮(RPE)细胞中分化iPS细胞。RPE细胞将用于治疗老年性黄斑变性患者。

The Center for Cellular Engineering (CCE) is working to develop and improve cancer cellular therapies including Dendritic Cell (DC) therapies, chimeric antigen receptor (CAR) T cell therapies and T cell engineered to express T cell receptors (TCRs) specific to tumor antigens. The laboratory is working to improve the methods used to produce Bone Marrow Stromal Cells (BMSCs) and induced pluripotent stem (iPS) cells for regenerative medicine applications. Dendritic cells are an important adjuvant for cancer vaccines. The CCE is currently producing DCs expressing HER2/neu to treat cancer patients whose tumors express this antigen. The lab has discovered that factors in the plasma from some people can inhibit the expression of HER2/neu by DCs. The CCE New Production Management (NPM) laboratory has developed and is manufacturing several CAR T cell therapies. CD22-CAR T cells and CD19/CD22-bispecific T cells are being manufactured in order to treat pediatric patients with B cell leukemia. Manufacturing of CD30-CAR T cells has recently been initiated. These CAR T cells are being used to treat adults with lymphomas. The laboratory has also developed anti-B Cell Maturation Antigen (BCMA) CAR T cells and anti-SLAMF7-CAR T cells to treat patients with multiple myeloma. The laboratory has developed procedures to manufacture CD19/CD22- CAR T cells using a completely automated instrument. Human Papillomavirus (HPV) infection is associated with a number of cancers. The NPM laboratory has developed a method to produce T cells that express a T cell receptor (TCR) that is specific for the HPV-16 oncoprotein E7. These cells will be used to treat patients with HPV-associated cervical and oropharyngeal cancers. The Cell Processing Laboratory is collaborating with investigators in the National Eye Institute to develop methods to manufacture iPS cells from CD34+ cells isolated from the blood and to differentiate the iPS cells in retinal pigment epithelial (RPE) cells. The RPE cells will be used to treat patients with age related macular degeneration.